Suita Research Center
| Representative | Yasutaka Sumida, Director of the Board, Managing Executive Officer |
|---|---|
| Location | 5-8 Nishi Otabi-cho, Suita, Osaka |
| Number of employees | 442 (As of March 31, 2025) |
FY2024 Results of RC Activities
| Occupational safety and health | Zero injuries with lost workdays*1, zero injuries without lost workdays*1 |
|---|---|
| Process safety and disaster prevention | Zero Class A and Class B process safety accidents |
| Environmental protection | Recycling 100% of waste |
In terms of occupational safety and health, we had zero injuries with lost workdays and zero injuries without lost workdays. We will continue to strengthen activities including hazard prediction and risk management.
In process safety and disaster prevention, we have systematically conducted initial response emergency drills, overall drills, joint drills with the fire department, and initial fire extinguishing training under the guidance of the fire department to improve our disaster preparedness. Additionally, to prevent the fading of accident experiences in the research division, we invited external lecturers to hold process safety seminars.
In environmental protection, we have maintained a 100% waste recycling rate. Furthermore, as part of our energy conservation measures, we are promoting the efficient operation of equipment.
We will continue to promote RC activities with the aim of achieving sustainable and safe research activities.
Member of the Board, Managing Executive Officer
Practical training on wearing protective equipment
On April 1, 2024, the amended Industrial Safety and Health Act was enacted, mandating the appointment of a Personal Protective Equipment (PPE) Management Supervisor at workplaces where workers are required to use protective equipment. In the research division, where various chemical substances are handled and protective equipment is used, we invited an instructor from the Japan Industrial Safety and Health Association (JISHA) to conduct practical training. A total of 32 employees, mainly PPE Management Supervisors, attended this training session.
The training consisted of both theoretical and practical sessions on protective equipment. During the practical session, participants had the opportunity to handle various types of protective equipment. There were active exchanges of questions and answers with the instructor and discussions among participants.
Feedback from participants included comments such as, “I was able to re-recognize the rationale for selecting protective equipment and the importance of maintenance,” and “I want to apply the knowledge I learned to my workplace to enhance safety awareness.” The training was highly evaluated as useful.
GMP*2 activities
SGP plant in Suita Research Center started operation as a GMP controlled plant in 2019. In SGP plant, we manufacture active pharmaceutical ingredients (APIs) of middle molecule drugs for commercial and investigational use. Middle molecule drug is a new modality expected to be applicable for various diseases, due to its high specificity to the target molecule. It is considered to have significant potential in various area.
As a manufacturer of API for this promising modality, we pursue reliable high quality of our products as well as operational safety in the manufacturing plant, so that reliable pharmaceutics can be provided which can be used with peace of mind. We will continuously work for further improvement and stabilization of the quality of our products under compliance of GMP on the basis of our underlying RC activities.
*2 GMP: Good Manufacturing Practice
